



Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/432,503
				Filing Date	November 2, 1999
				First Named Inventor	Cech, Thomas R.
				Art Unit	1635
				Examiner Name	Jon E. Angell
Sheet	2	of	3	Attorney Docket Number	015389-002611US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	2	BACHAND, F. & AUTEXIER, C., "Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions," <i>Mol. Cell. Biol.</i> 21:1888-97 (2001).	<input type="checkbox"/>	
	3	BRYAN, T. et al., "A mutant of <i>Tetrahymena</i> telomerase reverse transcriptase with increased processivity," <i>J. Biol. Chem.</i> 275:24199-207 (2000).	<input type="checkbox"/>	
	4	BRYAN, T. et al., "Telomerase reverse transcriptase genes identified in <i>Tetrahymena thermophila</i> and <i>Oxytricha trifallax</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 95:8479-84 (1998).	<input type="checkbox"/>	
	5	BRYAN, T. et al., "Telomerase RNA bound by protein motifs specific to telomerase reverse transcriptase," <i>Molec. Cell</i> 6:493-99 (2000).	<input type="checkbox"/>	
	6	COLGIN, L. et al., "The hTERT $\alpha$ splice variant is a dominant negative inhibitor of telomerase activity," <i>Neoplasia</i> 2(5):426-32 (2000).	<input type="checkbox"/>	
	7	EMBL Database entry Greenberg et al., AF051911, XP002091313 (April 6, 1998).	<input type="checkbox"/>	
	8	EMBL Database entry Martin-Rivera et al., AF073311, XP002091314 (September 9, 1998).	<input type="checkbox"/>	
	9	FARMERY, M. & BULLEID, N., "Major histocompatibility class I folding, assembly, and degradation: A paradigm for two-stage quality control in the endoplasmic reticulum," <i>Prog. Nucl. Acid Res. Mol. Biol.</i> 67:235-68 (2001).	<input type="checkbox"/>	
	10	FRIEDMAN, K. et al., "Essential functions of amino-terminal domains in the yeast telomerase catalytic subunit revealed by selection for variable mutants," <i>Genes Dev.</i> 13(21):2863-74 (1999).	<input type="checkbox"/>	
	11	HAERING, C. et al., "Analysis of telomerase catalytic subunit mutants <i>in vivo</i> and <i>in vitro</i> in <i>Schizosaccharomyces pombe</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 97:6367-72 (2000).	<input type="checkbox"/>	
	12	HAHN, W. et al., "Inhibition of telomerase limits the growth of human cancer cells," <i>Nature Med.</i> 5:1164-70 (1999).	<input type="checkbox"/>	
Examiner Signature				Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/432,503
				Filing Date	November 2, 1999
				First Named Inventor	Cech, Thomas R.
				Art Unit	1635
Examiner Name	Jon E. Angell				
Attorney Docket Number	015389-002611US				
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	13	LAI, C. et al., "RNA binding domain of telomerase reverse transcriptase," <i>Mol. Cell. Biol.</i> 21:990-1000 (2001).	<input type="checkbox"/>	
	14	LEEM et al., "The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions," <i>Oncogene</i> 21:769-77 (2002).	<input type="checkbox"/>	
	15	LI, H. et al., "Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells," <i>J. Biol. Chem.</i> 272:16729-32 (1997).	<input type="checkbox"/>	
	16	MEYERS, R., Ed., <u>Molecular Biology and Biotechnology, A Comprehensive Desk Reference</u> , Wiley-VCH, New York, p. 187 (1995).	<input type="checkbox"/>	
	17	PEREZ, H. et al., "Human formyl peptide receptor ligand binding domain(s). Studies using an improved mutagenesis/expression vector reveal a novel mechanism for the regulation of receptor occupancy," <i>J. Biol. Chem.</i> 269(36):22485-7 (1994).	<input type="checkbox"/>	
	18	SOLHEIM, J., "Class I MHC molecules: Assembly and antigen presentation," <i>Immunol. Rev.</i> 172:11-19 (1999).	<input type="checkbox"/>	
	19	XIA, J. et al., "Identification of functionally important domains in the N-terminal region of telomerase reverse transcriptase," <i>Mol. Cell. Biol.</i> 20:5196-207 (2000).	<input type="checkbox"/>	
	20	ZAKHAROVA, O. et al., "Structural constraints in the HIV-1 reverse transcriptase-primer/template complex for the initiation of DNA synthesis from primer tRNA <sup>Lys3</sup> ," <i>Biochem.</i> 37:13343-8 (1998).	<input type="checkbox"/>	

Examiner Signature	/Jon Eric Angell/	Date Considered	03/26/2009
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.